From product debuts to new research, here are five key developments in orthobiologics since May 6.
1. Tetrous' EnFix TAC demineralized bone fiber implants were used in their first cases. The new implants are the latest in the EnFix implant line for rotator cuff repair, according to a news release. The EnFix TAC is designed to address enthesis failure syndrome and comes in two configurations — TAC-O and TAC-T.
2. Physicians at Carmel, N.Y.-based Somers Orthopaedic & Spine Surgery Center have performed the first autologous live stem cell knee injection. The injection is performed under general anesthesia, and administers purified concentrated live stem cells derived from the patient's own abdominal fat.
3. New York City-based Hospital for Special Surgery launched a clinical trial that will evaluate the efficacy of concentrated bone marrow aspirate as an addition to ACL revision surgery. The randomized trial aims to determine if concentrated bone marrow aspirate can prevent chronic inflammation and osteoarthritis in ACL revision patients. The concentrated bone marrow aspirate in the study will come from the patient's own pelvic bones.
4. New York City orthopedic surgeon Steven Struhl, MD, has completed his first procedure using Cartiheal's Agili-C implant for regenerating articular cartilage. The Agili-C implant was approved by the FDA in March 2022 and is an off-the-shelf solution for cartilage and osteochondral defects in both traumatic and osteoarthritic joints.
5. OssDesign's Catalyst nanosynthetic bone graft was used in its 5,000th U.S. patient. Catalyst is designed to stimulate the formation of healthy bone tissue in spinal fusions and is made of a proprietary nanocrystalline structure that's reabsorbed and replaced by new tissue.